Jade Biosciences (JBIO)
NASDAQ:JBIO
Want to see JBIO full AI Analyst Report?
JBIO Stock Chart & Stats
$22.85
--
Market closed
$22.85
--
Day’s Range― - ―
52-Week Range$6.57 - $96.95
Previous CloseN/A
VolumeN/A
Average Volume (3M)127.19K
Market Cap
$1.23B
Enterprise Value$788.29M
Total Cash (Recent Filing)$336.16M
Total Debt (Recent Filing)$724.00K
Price to Earnings (P/E)―
Beta0.24
Next Earnings
May 18, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend Yield14.68%
Share Statistics
EPS (TTM)-0.45
Shares Outstanding49,316,288
10 Day Avg. Volume252,880
30 Day Avg. Volume127,195
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-35.83K
Enterprise Value/Ebitda-8.55
Forecast
1Y Price Target
$32.50Price Target Upside42.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPhase 1 development of JADE101 is proceeding on schedule, supporting delivery of first-in-human biomarker data that could validate the program's clinical potential.
Market OpportunityGrowing diagnosis rates and guideline shifts in IgA nephropathy could expand demand for a safer, more effective APRIL-targeting therapy, increasing commercial upside for a differentiated product.
Product DifferentiationJADE101's fully human design, novel epitope targeting and extended half-life aim to reduce anti-drug antibodies and enable deeper efficacy with less frequent dosing compared with first-generation APRIL therapies.
Bears Say
Competitive LandscapeMultiple APRIL and APRIL/BAFF candidates advancing toward regulatory filings, plus B-cell modulator programs from large pharmaceutical companies, could crowd the market and constrain market share for new entrants.
Financial PositionAbsence of revenue and a net loss that exceeded consensus highlight ongoing cash burn and increase the likelihood of near-term financing needs before commercial milestones are reached.
Program DelaysA delay in the JADE301 program relative to other programs could postpone key clinical readouts and diminish near-term visibility for the development pipeline.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences’s price range in the past 12 months?
Jade Biosciences lowest stock price was $6.57 and its highest was $96.95 in the past 12 months.
What is Jade Biosciences’s market cap?
Jade Biosciences’s market cap is $1.23B.
When is Jade Biosciences’s upcoming earnings report date?
Jade Biosciences’s upcoming earnings report date is May 18, 2026 which is in 20 days.
How were Jade Biosciences’s earnings last quarter?
Jade Biosciences released its earnings results on Mar 06, 2026. The company reported -$0.451 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.031.
Is Jade Biosciences overvalued?
According to Wall Street analysts Jade Biosciences’s price is currently Undervalued.
Does Jade Biosciences pay dividends?
Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 14.68%. See more information on Jade Biosciences dividends here
What is Jade Biosciences’s EPS estimate?
Jade Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Jade Biosciences have?
Jade Biosciences has 49,316,288 shares outstanding.
What happened to Jade Biosciences’s price movement after its last earnings report?
Jade Biosciences reported an EPS of -$0.451 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 1.225%.
Which hedge fund is a major shareholder of Jade Biosciences?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (42.23% Upside)
$32.50 (42.23% Upside)
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.45%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
100.52%
Trailing 12-Months
Company Description
Jade Biosciences
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$32.50
▲(42.23% Upside)
Technical Analysis
Ownership Overview
13.01% Insiders
16.74% Mutual Funds
0.03% Other Institutional Investors
63.43% Public Companies and
Individual Investors